SLC5A2 and type 1 diabetes mellitus: Adjuvant therapy with SGLT2 inhibitors reduces the total daily insulin dose in patients with T1DM, and ketone bodies increase when low-dose insulin is insufficient to inhibit lipolysis in peripheral adipose tissue.